Ver­tex signs in vi­vo gene edit­ing de­liv­ery pact for sick­le cell and tha­lassemia as it looks be­yond Cas­gevy

Ver­tex Phar­ma­ceu­ti­cals signed a three-year deal with Or­na Ther­a­peu­tics to use the RNA biotech’s de­liv­ery par­ti­cles to de­vel­op its next it­er­a­tion of gene edit­ing treat­ments …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER